Registry of adults with APS on blood thinners
Treatments studied
Part of Heart & circulation, Immune system & allergy clinical trials.
This study keeps an international registry of people with antiphospholipid syndrome (APS) who are taking direct oral blood thinners. It may help doctors better understand how APS patients do over time and improve future care, even if you’re not asked to change treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be an adult age 18 or older
- Have a confirmed diagnosis of APS (antiphospholipid syndrome) based on the revised Sapporo-Sydney criteria
- Be currently taking a direct oral blood thinner for at least 6 months, or be able to be followed for at least 6 months
- Have information available about your past blood clot and any return of clots
- Be willing to take part (not opposed) and able to provide follow-up information
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two types of blood thinners (vitamin K antagonists) in people with antiphospholipid syndrome, a condition where the immune system attacks healthy cells and increases blood clot risk. The goal is to see if one is better at preventing future blood clots.
This study keeps a registry to follow people with antiphospholipid syndrome (APS) who have had arterial blood clots (like stroke). It collects information about the treatment approach your clinician chooses to see how different antithrombotic regimens may perform and be tolerated.
This study is for children who have antiphospholipid syndrome (APS) and a history of blood vessel clots. Researchers want to learn more about APS in pediatric patients who have specific blood test signs and clot history.
This study looks at genetic (inherited) risk factors in people who have antiphospholipid antibodies and related symptoms. Your results may help researchers better predict who is at risk and improve care for antiphospholipid antibody syndrome.
This study looks at how platelet counts change over time in people with antiphospholipid syndrome (APS), a condition that can cause blood clots and pregnancy problems. It may help doctors better understand and manage low platelets in APS patients.
This study tests whether it is safe to stop taking blood thinners (vitamin K antagonists) if the antiphospholipid antibodies that caused your condition have been gone for at least a year. If you qualify, stopping treatment might reduce your risk of bleeding and improve your quality of life.
Hear when a new Antiphospholipid Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.